Clew to promote return of drug Thalidomide

Clew Communications is to provide PR support for the planned relaunch of controversial drug Thalidomide.

US company Pharmion has called in the agency ahead of an expected launch across the UK and Europe in 2008.

The drug hit the headlines in the 1970s when it emerged that its use in treating sickness during pregnancy in the previous decade had ­resulted in birth defects. But following its withdrawal, the drug has been found to be ­effective in treating leprosy and has been used unlicensed to treat multiple ­myeloma (MM).

Pharmion has applied for a licence and is currently awaiting a verdict from the European Agency for the Evaluation of Medicinal Products.

Clew landed the ­account without a pitch. The agency’s MD Mary Hicks said: ‘The drug’s history is a challenge but less so than we expected. Pharmion is not trying to hide away from the name.

‘Although it did not own the drug in the 1960s, it has inherited its history and future. It now has a new face and has been shown to be hugely effective in treating MM.’

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Would you like to post a comment?

Please Sign in or register.